德展健康(000813.SZ):公司實控人將變更為新疆國資委
格隆匯5月13日丨德展健康(000813.SZ)公佈,公司控股股東美林控股及其一致行動人凱世富樂9號與凱迪投資簽署了《股份轉讓協議》,轉讓美林控股及凱世富樂持有的公司167,886,987股股份(佔公司總股本的7.49%),交易價格為6.6元/股,交易總價約11.08億元,如此次股份轉讓事項順利實施完畢,公司控制權將發生變更。
若此次交易實施完成,凱迪投資及其一致行動人將持有公司533,886,958股股份,佔公司總股本的23.82%。公司控股股東將變更為凱迪投資,公司實際控制人將變更為新疆國資委。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.